secwatch.observer — SEC 8-K summary
======================================

Issuer:     HAEMONETICS CORP (HAE)
CIK:        0000313143
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0000313143-24-000009
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Haemonetics to acquire Attune Medical for $160M upfront; device complements EP portfolio
--------------------------------------------------------------------------------

- Upfront cash $160M plus contingent consideration based on sales growth and milestones.
- Attune Medical's ensoETM device reduces esophageal injury during cardiac ablation; revenue $22M in 2023, doubled YoY.
- Transaction expected to close in Q1 fiscal 2025 (April-June 2024) subject to customary conditions.
- Haemonetics expects immediate accretion to revenue and earnings growth; financed via cash and revolver.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/313143/000031314324000009/0000313143-24-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/313143/000031314324000009/hae-20240305.htm
  HTML page:      https://secwatch.observer/filing/0000313143-24-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer